A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Thioureidobutyronitrile (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Innovation Pharmaceuticals
- 14 Sep 2017 According to an iPharma media release, the company expects initial primary results in 4th quarter 2017.
- 14 Sep 2017 According to an iPharma media release, a new clinical site has been added is now actively enrolling patients.
- 10 May 2017 According to a Cellceutix media release, this trial is expected to complete in 2H2017.